Callan JMB Inc

Callan JMB Inc(CJMB)股票分析

$2.200

-0.200 (-9.09%)收盤時

Loading chart…
最高
2.390
開盤
2.390
成交量加權均價
2.26
成交量
45.40K
市值
—
最低
2.195
成交金額
102.67K
企業價值/稅息折舊攤銷前利潤(TTM)
0.00

Callan JMB Inc. is a vertically integrated logistics and fulfillment company, which provides thermal management logistics solutions to the life sciences industry through a combination of proprietary packaging, information technology and specialized cold chain logistics knowhow. The Company provides comprehensive alternatives to all logistics solutions and services utilized for frozen shipping in the life sciences industry (personalized medicine, cell therapies, stem cells, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, organs, biopharmaceuticals, infectious substances, and other commodities that require continuous exposure to cryogenic or frozen temperatures). Its Ship2Q ultraviolet disinfection process (Safe Hygienic Irradiation Performance Process & Qualification) ensures fitness, thermal reliability, and cleanliness of the system components within the manufacturers specifications equal to new off-the-shelf shipper systems.

AI 分析 of Callan JMB Inc (CJMB)

賣出

Callan JMB Inc. is not a good buy right now due to its recent financial struggles and negative performance indicators. The stock has a current price of $2.20, which is down 3.51% over the last 5 days and has seen a significant decline of 47.55% over the past year. Additionally, the company's forward P/E ratio is 0, indicating no expected earnings growth, and the gross margin has fluctuated, currently standing at 55.07%, which is positive but overshadowed by the overall financial losses. The main risk is the net income loss of $3,215,054 in Q1 2026, which raises concerns about the company's sustainability and profitability moving forward.

估值指標

Callan JMB Inc(CJMB)目前預期本益比為 0.00,5 年平均預期本益比為 0.00。

預期本益比

嚴重低估
5 年均值 P/E
0.00
目前P/E
0.00
高估
0.00
低估
0.00

預期 EV/EBITDA

嚴重低估
5 年均值 EV/EBITDA
0.00
目前EV/EBITDA
0.00
高估
0.00
低估
0.00

預期股價營收比

嚴重低估
5 年均值 P/S
0.00
目前P/S
0.00
高估
0.00
低估
0.00

Alphio AI 對 CJMB 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%CJMB

$7.05

情境價格

基

基準

基準 · 50%CJMB

$6.02

情境價格

悲

悲觀

悲觀 · 25%CJMB

$5.29

情境價格

事件時間軸

2026-08-11 (ET)

08:30:00

Callan JMB and Alabama State University Form Strategic Joint Venture with $60M Investment

2026-07-16 (ET)

09:30:00

Callan JMB Forms Strategic Partnership with Alabama State University

2026-07-08 (ET)

17:30:00

Callan JMB Forms Strategic Partnership with Alabama State University

2026-05-20 (ET)

09:10:00

Callan JMB Expands Public Sector Contract Worth Approximately $1.05M

2026-04-20 (ET)

08:40:00

Callan JMB Announces 150-Acre Atlas Complex in Alabama

資訊

CJMB 常見問題 —— 由 Alphio AI 解答

Callan JMB Inc. is a vertically integrated logistics and fulfillment company, which provides thermal management logistics solutions to the life sciences industry through a combination of proprietary packaging, information technology and specialized cold chain logistics knowhow. The Company provides comprehensive alternatives to all logistics solutions and services utilized for frozen shipping in the life sciences industry (personalized medicine, cell therapies, stem cells, cell lines, vaccines, diagnostic materials, semen, eggs, embryos, cord blood, organs, biopharmaceuticals, infectious substances, and other commodities that require continuous exposure to cryogenic or frozen temperatures). Its Ship2Q ultraviolet disinfection process (Safe Hygienic Irradiation Performance Process & Qualification) ensures fitness, thermal reliability, and cleanliness of the system components within the manufacturers specifications equal to new off-the-shelf shipper systems. It operates in the Industrials sector.

Callan JMB Inc. is not a good buy right now due to its recent financial struggles and negative performance indicators. The stock has a current price of $2.20, which is down 3.51% over the last 5 days and has seen a significant decline of 47.55% over the past year. Additionally, the company's forward P/E ratio is 0, indicating no expected earnings growth, and the gross margin has fluctuated, currently standing at 55.07%, which is positive but overshadowed by the overall financial losses. The main risk is the net income loss of $3,215,054 in Q1 2026, which raises concerns about the company's sustainability and profitability moving forward.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易